Navigation Links
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
Date:8/24/2009

HOERSHOLM, Denmark, August 24 /PRNewswire/ --

- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders

- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery

- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completio
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... 2013 India’s vast and growing ... be worth up to a billion dollars per ... government is taking serious action to better regulate ... This presentation will examine:, ,     Recent ...     Immediate and long term impacts ,     Foreseeable ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
(Date:6/18/2013)... A million electric cars could be on roads across North ... of research by the United States Department of Energy, Los ... Zhongwei Chen is part of a team led by the ... replace the expensive platinum catalysts in fuel cells. , "One ... in vehicles is the cost of the units. The pure ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2
... conductivities seen in metal wires, and that may light up ... researchers. A Rice lab made such a cable from ... standard line voltage -- a true test of the novel ... the future. The work appears this week in ...
... Sept. 7, 2011 Cellectis (Alternext: ALCLS), ... that its nuclease production capacity has increased ... Industrialization of the nuclease manufacturing gives Cellectis ... subsidiary of Cellectis, the potential to supply ...
... 2011 Ardea Biosciences, Inc. (Nasdaq: RDEA ) ... with the U.S. Food and Drug Administration (FDA) and successfully ... lesinurad Phase 3 development plan: the overall size and design ... the total safety database proposed for NDA filing, manufacturing plans ...
Cached Biology Technology:Rice researchers power line-voltage light bulb with nanotube wire 2Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
(Date:6/19/2013)... Tanzania is playing a vital role in the survival ... response to climate and environmental changes, according to new ... on savannah birds from the Tanzanian Bird Atlas project ... decades - the researchers found that they are using ... areas further west where dry seasons are getting longer, ...
(Date:6/19/2013)... Science Consortium (PISC) is extremely disappointed that the ... upheld a decision that requires Dow Benelux B.V.to ... The study will use approximately 1160 animals and ... the substance dipropylene glycol methyl ether acetate (DPMA) ... Regulation on the Registration, Evaluation, Authorisation and Restriction ...
(Date:6/19/2013)... A team of researchers at the University of ... outer coating of HIV, that could be potential ... avoid generating resistance. These new agents are quite ... The research was published in the June 2013 ... Chemotherapy . , The first of many probable ...
Breaking Biology News(10 mins):Protected areas provide African birds with stepping stones to survival 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... , ANN ARBOR, Mich.---Air pollution from industrial sources ... academic success, according to a new study from ... that schools located in areas with the state,s ... attendance rates---an indicator of poor health---as well as ...
... New findings from University of Utah School of Medicine researchers show ... of patients who have chronic fatigue syndrome (CFS). These findings ... CFS to XMRV. The study, performed by a team of ... associate professor of pathology, was published May 4, 2011, in the ...
... FASEB MARC (Minority Access to Research Careers) Program ... Genetics Society of America (GSA) Mouse Genetics conference in ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
Cached Biology News:Air pollution near Michigan schools linked to poorer student health, academic performance 2Air pollution near Michigan schools linked to poorer student health, academic performance 3Air pollution near Michigan schools linked to poorer student health, academic performance 4Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 2Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 3
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
Biology Products: